Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity PharmaTimesLatebreaking EULAR results highlight sustained responses through week 52Immunology & InflammationRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) PharmaTimes Latebreaking EULAR results highlight sustained responses through week 52 Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnershipNext: Alnylam hops on AI train with up to $2B Inceptive partnership Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
